Navigation Links
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Date:9/4/2007

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced the results of a controlled clinical trial, published in the September 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol, a selective beta 1-blocker with vasodilating properties, significantly reduced sitting diastolic and systolic blood pressure among patients with mild-to-moderate hypertension. The study - the first to evaluate the drug in a U.S. population - also found that nebivolol was well tolerated in comparison to placebo and was not associated with adverse changes in blood glucose levels. Nebivolol is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension.

"Next-generation beta blockers, such as nebivolol, represent a step forward in the treatment of hypertension," said Robert J. Weiss, M.D., Director Cardiovascular Research, Maine Clinical Research. "As we saw in the study, nebivolol demonstrated efficacy with a low incidence of side effects typical of traditional beta blockers, such as fatigue, erectile dysfunction, and depression. In addition, there were no clinically significant changes in glucose levels, which makes nebivolol useful in patients with certain metabolic disorders."

In the double-blind, placebo-controlled study, a total of 909 patients were randomized to receive placebo (81 patients) or nebivolol (828 patients) dosed at 1.25mg, 2.5mg, 5mg, 10mg, 20mg or 40mg once daily for up to 12 weeks. The 40mg dose was included to study safety only. The study concluded that nebivolol, at doses of 1.25mg to 20mg once daily, significantly reduced both trough sitting diastolic and systolic blood pressure. Additionally, the study demonstrated that nebivolol was well tolerated by comparison to placebo treatment. Headache was the most common treatment-related adverse event experienced by 7.1% of the pooled nebivolol-treated patients (dosages of 1.25mg to 40mg once daily) and 7.4% of the placebo-treated patients. Of note, in the pooled nebivolol group, the incidence of AEs commonly associated with traditional beta blocker use, including fatigue (3.6% vs. 2.5% with placebo), erectile dysfunction (0.2%), and depression (0.2%) was low. Moreover, nebivolol was not associated with adverse changes in blood glucose values.

"The publication of nebivolol's first U.S. clinical trial further reinforces its longstanding use in patients worldwide," said Neil Shusterman, M.D., Senior Vice President, Clinical Development, Forest Research Institute. "The majority of Americans afflicted with this disease are still not controlled, so clearly there is a need for more treatment options. This study showed that nebivolol significantly lowered blood pressure in patients with mild-to-moderate hypertension and we anticipate it will be an important therapy for physicians."

About Hypertension

Hypertension, also known as high blood pressure, affects approximately 72 million people in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range. If left untreated, hypertension can eventually damage important organs such as the heart, brain, eyes or kidneys. High blood pressure greatly increases the risk of certain health problems such as stroke, heart attack, and kidney failure.

About Nebivolol

Nebivolol is a selective beta 1-blocker with vasodilating properties and is already approved and successfully marketed for the treatment of hypertension in more than 50 countries outside of North America.

About Forest Laboratories and Its Products

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R) * (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

* Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007, and on Form 10-Q for the period ended June 30, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Northridge, CA (PRWEB) , ... March 24, 2017 ... ... Dr. Ramin Assili, announce that they are now offering treatments for sleep apnea ... treated at dental offices. Sleep apnea , specifically the obstructive type, is ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
Breaking Medicine News(10 mins):